Ian has held global leadership positions with multinational life science companies (ICI, AstraZeneca, Lonza, ChiRex and Rhodia).  He was also previously co-founder, majority owner, chairman, and managing director of Arcinova, a high-growth CDMO. Ian also served as the managing partner of Shott Trinova, where he invested in a portfolio of life science businesses. Ian is currently a Non-Executive Director of Quotient Sciences, Executive Chairman of Ingenza and a senior adviser to Permira.

Ian has held positions as a member of the Governing Board of Innovate UK and President of the Institution of Chemical Engineers. He was made CBE for services to Chemical Engineering in 2009 and has served as a Specialist Adviser to the House of Lords Select Committee on Science and Technology.

Kjell has extensive experience from executive and board positions across tech and biotech sectors, including as investor and Chair at P53 Invest AS. Previously he served as Regional Director Europe North at Cisco Systems from 2005 until 2010 and in several management positions in Tandberg, which was acquired by Cisco Systems. In 2010 he founded Stavanger Venture AS, which invests in technology companies. He also has extensive investment experience and in venture capital and portfolio management and is an early investor in Arctoris.

Mark is currently a Partner, LP and Investment Committee member at Kindred Capital, a European seed-stage venture fund, based in London. He was a General Partner at Balderton Capital/Benchmark Europe from 2002 through 2015, and an EIR at Benchmark Capital in 1999/2000.
He spent the prior 15 years at Goldman Sachs, where he was a General Partner and Management Committee member. He studied Economics at both University of Oxford and Queen’s University in Canada. Mark has been a long-term investor in and mentor to Arctoris.

David Knox is a founding director and shareholder of Future Planet Capital who is inspired by, and committed to working with, the team to address the world’s biggest challenges by connecting investors with outstanding impactful innovation.

Having trained in the fields of medical and actuarial science, David has enjoyed an extensive and successful career in financial services and as an entrepreneur.  He has worked with Munich Re, he became a partner at Cazenove and subsequently Head of Research and a member of the Executive Management Committee at J.P. Morgan Cazenove and he was CEO of Oriel Securities.  He established Lazarus Research, an independent research advisory firm and he holds a number of other directorships.  David is heavily involved in a number of voluntary and charitable roles and he is a keen sportsman.

Kinga has a PhD from Cancer Research UK and University College London. She completed her Postdoc as a Sir Henry Wellcome Fellow at King’s College London and published in both Nature and Science Magazine. She worked as a BD consultant across translational oncology and precision medicine at Champions Oncology and Cerba Research before joining Arctoris. She is passionate about science communication and patient participation in research.

A chartered accountant with over 15 years of senior finance leadership experience. Previous positions included positions at PwC and Sony Music and consulting roles supporting startups and scaleups with fundraising and financial strategy.